John H Holcombe
Overview
Explore the profile of John H Holcombe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
668
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rees T, Curtis B, Gaskins K, Sierra-Johnson J, Jiang H, Liu R, et al.
Endocr Pract
. 2013 Dec;
20(5):389-98.
PMID: 24325997
Objective: To evaluate the efficacy and safety of insulin lispro in the treatment of patients with type 2 diabetes (T2DM) who had a body mass index (BMI) ≥30 kg/m2 (obese)...
2.
Curtis B, Rees T, Gaskins K, Sierra-Johnson J, Liu R, Jiang H, et al.
Aging Clin Exp Res
. 2013 Aug;
26(1):77-88.
PMID: 23959960
Background And Aims: Glycemic control in geriatric patients with type 2 diabetes (T2DM) remains clinically challenging. The objective of this study was to compare the safety and efficacy of insulin...
3.
Rosenstock J, Klaff L, Schwartz S, Northrup J, Holcombe J, Wilhelm K, et al.
Diabetes Care
. 2010 Mar;
33(6):1173-5.
PMID: 20332357
Objective: To assess the effects of exenatide on body weight and glucose tolerance in nondiabetic obese subjects with normal or impaired glucose tolerance (IGT) or impaired fasting glucose (IFG). Research...
4.
Zhao Y, Ye W, Le T, Boye K, Holcombe J, Swindle R
Curr Med Res Opin
. 2009 Feb;
25(3):585-97.
PMID: 19232033
Objective: To examine medical conditions associated with diabetic neuropathy (DN) and to identify drivers of healthcare charges and utilization using administrative claims. Methods: The study examined commercially-insured under-age-65 individuals with...
5.
Zhao Y, Ye W, Boye K, Holcombe J, Hall J, Swindle R
J Diabetes Complications
. 2008 Oct;
24(1):9-19.
PMID: 18930413
Introduction: Diabetic neuropathy (DN) is a common complication associated with diabetes. This study assesses the prevalence of other diabetes-related complications or comorbidities among DN patients and its marginal contribution to...
6.
DeFronzo R, Okerson T, Viswanathan P, Guan X, Holcombe J, MacConell L
Curr Med Res Opin
. 2008 Sep;
24(10):2943-52.
PMID: 18786299
Background: This study evaluated the effects of exenatide, a GLP-1 receptor agonist, and sitagliptin, a DPP-4 inhibitor, on 2-h postprandial glucose (PPG), insulin and glucagon secretion, gastric emptying, and caloric...
7.
Schwartz S, Ratner R, Kim D, Qu Y, Fechner L, Lenox S, et al.
Clin Ther
. 2008 Jun;
30(5):858-67.
PMID: 18555933
Objective: The aim of this study was to examine the glucose-lowering effect of exenatide over 24 hours in patients with type 2 diabetes with inadequate glycemic control using metformin, with...
8.
Brodows R, Qu Y, Johns D, Kim D, Holcombe J
Curr Med Res Opin
. 2008 Apr;
24(5):1395-7.
PMID: 18394265
In this report, we quantify the effects of exenatide and glargine on the relative contributions of fasting and postprandial glucose (PPG) excursion to overall hyperglycemia based on self-monitored blood glucose....
9.
Klonoff D, Buse J, Nielsen L, Guan X, Bowlus C, Holcombe J, et al.
Curr Med Res Opin
. 2007 Dec;
24(1):275-86.
PMID: 18053320
Background: Exenatide, an incretin mimetic for adjunctive treatment of type 2 diabetes (T2DM), reduced hemoglobin A(1c) (A1C) and weight in clinical trials. The objective of this study was to evaluate...
10.
Buse J, Klonoff D, Nielsen L, Guan X, Bowlus C, Holcombe J, et al.
Clin Ther
. 2007 Mar;
29(1):139-53.
PMID: 17379054
Background: Exenatide, an incretin mimetic for adjunctive treatment of type 2 diabetes mellitus (T2DM), reduced glycosylated hemoglobin (HbA(1c)) and weight in 30-week placebo-controlled trials. Some patients were followed up in...